SalioGen Therapeutics Appoints Kali Stasi, M.D., Ph.D. as Chief Medical Officer

-Dr. Stasi brings to SalioGen 30 years of experience in ophthalmology and genetic medicine- LEXINGTON, Mass. , Aug.

19, 2024 /PRNewswire/ -- SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on its novel Gene CodingTM technology, today announced the appointment of Kalliopi "Kali" Stasi, M.D., Ph.

D. as Chief Medical Officer. In this position, Dr.

Stasi will be responsible for bringing the company's development candidate SGT-1001 into the clinic by mid-2025 as a one-time treatment for Stargardt disease and continuing to develop the company's Gene Coding technology for other inherited retinal diseases and cystic fibrosis. "Dr. Stasi brings to SalioGen three decades of expertise in ophthalmology and a proven track record of advancing genetic medicines from early- and late-stage clinical development through commercialization," said Jason Cole , CEO of SalioGen Therapeutics.

"Her clinical vision and leadership will enhance our ability to continue pushing the boundaries of genetic medicine for patients and families, and we're excited to welcome Dr. Stasi to our team." "SalioGen's novel Gene Coding technology holds tremendous potential for overcoming the limitations of other genetic medicine approaches, significantly expanding the universe of diseases we can address by integrating full genes with high specificity," said Dr.

Stasi. "I'm very excited to work with the SalioGen team to accelerate the positive impact this technology can have.